Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/13199
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPhillips, P A-
dc.contributor.authorHutchins, A M-
dc.contributor.authorBurrell, Louise M-
dc.contributor.authorRisvanis, John-
dc.contributor.authorJohnston, Colin I-
dc.date.accessioned2015-05-16T02:59:37Z
dc.date.available2015-05-16T02:59:37Z
dc.date.issued1994-07-11-
dc.identifier.citationEuropean Journal of Pharmacology; 259(3): 325-9en_US
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/13199en
dc.description.abstractArginine vasopressin binding site characterisation was performed on purified nuclei and plasma membranes from livers of Sprague-Dawley rats. [125I][d(CH2)5,Sarc7,Arg8]vasopressin, a selective V1 vasopressin receptor antagonist radioligand, bound to the nuclei in a protein concentration and time dependent manner. Scatchard analysis of nuclear binding sites revealed a single binding site with maximal binding site density (Bmax) of 115 +/- 13 fmol/mg protein and affinity (KD) of 5.2 +/- 0.7 nM. Plasma membrane binding demonstrated a Bmax of 529 +/- 25 fmol/mg protein and KD of 1.9 +/- 0.1 nM. The displacement profile for nuclear binding sites using vasopressin analogues was similar to that for plasma membrane binding sites and was typical of a V1 vasopressin receptor type. There was no evidence of V2-like vasopressin receptor binding using [3H]des-Gly-NH9(2)[d(CH2)5,D-Ile2,Ile4,Arg8]vasopressi n, a selective V2 vasopressin receptor radioligand, in the nuclear or membrane fractions. These results suggest the existence of nuclear V1-like vasopressin binding sites.en_US
dc.language.isoenen
dc.subject.otherAnimalsen
dc.subject.otherArginine Vasopressin.analogs & derivatives.pharmacokineticsen
dc.subject.otherCell Membrane.drug effects.metabolismen
dc.subject.otherCell Nucleus.drug effects.metabolismen
dc.subject.otherDNA.biosynthesisen
dc.subject.otherFemaleen
dc.subject.otherIn Vitro Techniquesen
dc.subject.otherLigandsen
dc.subject.otherLiver.drug effects.metabolismen
dc.subject.otherProtein Biosynthesisen
dc.subject.otherRatsen
dc.subject.otherRats, Sprague-Dawleyen
dc.subject.otherReceptors, Vasopressin.drug effects.metabolismen
dc.subject.otherVasopressins.pharmacokineticsen
dc.titleV1-like [Arg8]vasopressin binding sites occur in rat hepatocyte nuclei.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleEuropean Journal of Pharmacologyen_US
dc.identifier.affiliationMedicine (University of Melbourne)en_US
dc.description.pages325-9en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/7982462en
dc.type.contentTexten_US
dc.type.austinJournal Articleen
local.name.researcherBurrell, Louise M
item.grantfulltextnone-
item.openairetypeJournal Article-
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
crisitem.author.deptCardiology-
crisitem.author.deptGeneral Medicine-
crisitem.author.deptMedicine (University of Melbourne)-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

26
checked on Nov 22, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.